65,437 trials
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 9.76; 9.79 µg/mL
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,737.00; 3,051.76 pg/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 8.5858; 9.2170 µg/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 630.45; 631.49 ng/mL
Diabetes
Primary: Number of Participants That Rated 80% of Tasks as Very Simple, Simple, or Neither Simple Nor Difficult (Ease of Use of the Software Program) — 46 Participants — p=0.0421
Rotavirus
Primary: Serum Anti-Rotavirus IgA Response — 89; 7 Participants — p=0.003
Healthy
Primary: Cmax - Maximum Observed Concentration — 799.78; 810.40 ng/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 573.29; 550.55 ng/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 633.96; 700.79 ng/mL
Hepatitis C Virus Infection
Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale
Rotavirus Disease
Primary: Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1 — 12.7; 13.5 mIU/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 830.39; 880.78 ng/mL
Excessive Sleepiness · Shift Work Sleep Disorder
Primary: Multiple Sleep Latency Test (MSLT) — 3.1; 0.4 Minutes — p=<0.0001
Hypertension
Primary: Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring — -21.4 mm Hg — p=<0.0001
Pain
Primary: Acetylcholine Concentration in Cerebrospinal Fluid — 406; 383 picograms per milliliter (pg/ml)